Agenus Inc (NASDAQ:AGEN) — Market Cap & Net Worth
Market Cap & Net Worth: Agenus Inc (AGEN)
Agenus Inc (NASDAQ:AGEN) has a market capitalization of $307.42 Million ($307.42 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14812 globally and #3502 in its home market, demonstrating a 5.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Agenus Inc's stock price $7.22 by its total outstanding shares 45009670 (45.01 Million). Also see AGEN asset base for a full breakdown of the balance sheet.
Agenus Inc Market Cap History: 2015 to 2026
Agenus Inc's market capitalization history from 2015 to 2026. Data shows change from $4.01 Billion to $324.97 Million (-21.20% CAGR). Also see AGEN cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Agenus Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #403 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1440 of 3165 |
Weight: Agenus Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Agenus Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Agenus Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Agenus Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.24x
Agenus Inc's market cap is 1.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1228.96x
Agenus Inc's market cap is 1228.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.64 Billion | $22.57 Million | -$127.00 Million | 161.23x | N/A |
| 2017 | $2.88 Billion | $42.88 Million | -$120.69 Million | 67.16x | N/A |
| 2018 | $2.10 Billion | $36.78 Million | -$159.69 Million | 57.16x | N/A |
| 2019 | $3.60 Billion | $150.05 Million | -$107.66 Million | 23.96x | N/A |
| 2020 | $2.81 Billion | $88.17 Million | -$180.91 Million | 31.86x | N/A |
| 2021 | $2.84 Billion | $295.67 Million | -$23.93 Million | 9.62x | N/A |
| 2022 | $2.12 Billion | $98.02 Million | -$220.07 Million | 21.63x | N/A |
| 2023 | $745.27 Million | $156.31 Million | -$245.76 Million | 4.77x | N/A |
| 2024 | $123.33 Million | $103.46 Million | -$227.21 Million | 1.19x | N/A |
| 2025 | $141.33 Million | $114.20 Million | $115.00K | 1.24x | 1228.96x |
Competitor Companies of AGEN by Market Capitalization
Companies near Agenus Inc in the global market cap rankings as of September 18, 2026. Review AGEN tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Agenus Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Agenus Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Agenus Inc's market cap moved from $4.01 Billion to $ 324.97 Million, with a yearly change of -21.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $324.97 Million | +129.94% |
| 2025 | $141.33 Million | +14.60% |
| 2024 | $123.33 Million | -83.45% |
| 2023 | $745.27 Million | -64.85% |
| 2022 | $2.12 Billion | -25.47% |
| 2021 | $2.84 Billion | +1.26% |
| 2020 | $2.81 Billion | -21.87% |
| 2019 | $3.60 Billion | +71.01% |
| 2018 | $2.10 Billion | -26.99% |
| 2017 | $2.88 Billion | -20.87% |
| 2016 | $3.64 Billion | -9.25% |
| 2015 | $4.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Agenus Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $307.42 Million USD |
| MoneyControl | $307.42 Million USD |
| MarketWatch | $307.42 Million USD |
| marketcap.company | $307.42 Million USD |
| Reuters | $307.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more